Navigation Links
Isis and Collaborators Present New Research at the ATVB Annual Conference
Date:5/1/2009

vels of triglycerides and apoC-III.

Isis scientist, J. Crosby, presented new research titled "Antisense oligonucleotide-mediated depletion of Factor XI results in effective anticoagulation with a favorable risk/benefit profile in mice" demonstrating that antisense drugs that inhibit Factor XI can prevent thrombus formation in models of stroke without causing an increase in bleeding, the most common side effect observed with currently available antithrombotic agents. The Isis antisense drug inhibiting Factor XI is in advanced research and representative of significant advances in creating antisense drugs that can more safely reduce undesired clotting.

"Factor XI is the first representative drug candidate for development from our new thrombosis effort. It is another example of the power of our antisense technology to develop new drugs to nearly any genomic target," said Brett Monia, Ph.D., Vice President of Drug Discovery and Corporate Development at Isis Pharmaceuticals. "After rapidly and efficiently evaluating individual clotting factors produced in the liver, we selected Factor XI as the optimal target to inhibit thrombosis without causing bleeding. In addition to Factor XI, we will have drugs that inhibit other individual clotting factors that demonstrate potential therapeutic benefit and represent other novel approaches to treating cardiovascular disease."

Isis scientist, A. Mullick, also presented new research titled "Antisense inhibition of apolipoproteinC-III mitigated features of metabolic syndrome and reduced atherosclerosis in LDL receptor knockout mice" showing the ability of antisense drugs in a late-stage research program targeting apoC-III to selectively reduce triglycerides in both liver and blood. Antisense drugs that selectively reduced levels of apoC-III dramatically reduced triglycerides and atherosclerosis in animal models.

"The potential to add an apoC-III inhibitor in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
2. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds ... Potassium Nitrate Industry" and "2014 Deep Research Report ... reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice ... causes on July 30. "Sorrento is deeply saddened ... colleague. Our immediate thoughts go to Amar,s family and friends," ... Executive Officer. Mr. Singh joined Sorrento in ...
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Jan. 9, 2012    Lehigh Valley Technologies, Inc. (LVT) ... recently completed inspection by the U.S. Food and ... completed an onsite inspection with no Form 483 ... were no negative observations relating to cGMP (current ...
... Inc.,s ability to craft the pessary balloons that enhance ... commitment to premium quality output and complete mastery of ... Today,s pessaries are precision-manufactured medical devices that provide pelvic ... variety of gynecologic conditions, including prolapse. In years past, ...
Cached Medicine Technology:MedPlast's Pessary Balloon Manufacture Showcases Multi-Function Technical Mastery 2
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... Cincinnati, Ohio (PRWEB) August 01, 2014 ... in-home care for seniors, is honored to be recognized as ... prestigious award is given to home care providers who rank ... satisfaction categories, based on monthly satisfaction interviews conducted by Home ... recognize the leading home care businesses, the best of the ...
(Date:8/1/2014)... In recent years, minimally invasive aesthetic injectable procedures have ... women are seeking age-defying treatments. As Botulinum toxin ... a growing number of nonaesthetic health professionals have emerged ... Small, MD and Henry M. Spinelli, MD from the ... and Kathleen M. Kelly, MD from Columbia University in ...
(Date:8/1/2014)... 2014 CapsCanada, a leading provider ... a new K-CAPS® (HPMC capsules) manufacturing facility in ... plans last year while experiencing growing global demand ... Manager, “KCAPS® are currently sold in more than ... “Compared to other HPMC capsules, K-CAPS® have exceptional ...
(Date:8/1/2014)... MA (PRWEB) August 01, 2014 For ... even when memory is still within the normal range, ... warning signs of future decline. This merits a closer ... in the August 2014 Harvard Men's Health Watch ... that if they forget where their keys are they ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
... Four-legged heroes -- cats, too -- are maintaining the veterinary ... most of America,s blood donors, JJ and Logan are unaware ... saved. , But over a three-year period, the two healthy ... numerous canine patients survive surgeries and illnesses to play "fetch" ...
... Colo., April 18 Mesa Laboratories,Inc., (Nasdaq: MLAB ... will participate in a Health-Care Trade Policy Mission led ... selected as one of 15 companies,to accompany Under Secretary ... purpose of the mission is to provide a forum ...
... ROSEVILLE, Calif., April 18 CoolTouch Inc., ... introduction,of their new CoolBlue Duet(TM) laser lipolysis suction ... CoolLipo(TM) 1320 laser system.,Using a standard liposuction cannula, ... in one action, which dramatically reduces,the time of ...
... Supermarket,Company is alerting customers to a voluntary recall by Chang ... a sell by date of April 19,2008 and a UPC ... recalled because of the possible presence of,Listeria bacteria. Contamination with ... public health., Upon being notified of the recall, Stop ...
... April 17 The state,s Life Sciences Discovery,fund ... phase 1 clinical-trials,program to test new therapies for ... this evening, the grant is among the first,funded ... novel therapies targeted to treat solid tumors, in,collaboration ...
... cancer may have an Achilles, heel, report suggests , , THURSDAY, ... forced metastatic melanoma into remission for the first time, report ... case involves a 79-year-old woman with melanoma tumors in several ... in a gene called KIT, so the patient was enrolled ...
Cached Medicine News:Health News:Donor Dogs Give the Gift of Life 2Health News:Donor Dogs Give the Gift of Life 3Health News:Donor Dogs Give the Gift of Life 4Health News:CoolTouch Introduces CoolBlue Duet(TM) Laser Lipolysis Suction Handpiece 2Health News:Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2
... The RetCam II is a mobile, self-contained system ... office. It provides state-of-the-art Wide-Field Pediatric Retinal Imaging. ... entire exam and document almost the entire retina with ... RetCam II is our 3 CCD medical grade digital ...
... The new Riata ... physicians even more versatility ... high defibrillation thresholds (DFTs)., ... lead family allows physicians ...
... of use with high software functionality ... guided system for neurosurgery that is ... With a 50% usage rate and ... 500 physicians, VectorVision Cranial is the ...
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
Medicine Products: